Concerns about anti-vascular endothelial growth factor therapy for exudative age-related macular degeneration treatment / 中华眼底病杂志
Chinese Journal of Ocular Fundus Diseases
; (6): 6-8, 2010.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-380077
Biblioteca responsável:
WPRO
ABSTRACT
The introduction of anti-vascular endothelial growth factor (VEGF) therapy represents a landmark in the management of wet age-related macular degeneration (AMD).However,as a new therapy,several problems such as durability of the therapeutic effects,medication side effects,and medication selection have emerged.We should make appoint of improving the therapeutic effect and safety by realizing the limitation of the therapy,monitoring the clinical potential adverse reactions of anti-VEGF agents,and recommending individualized treatment.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Ocular Fundus Diseases
Ano de publicação:
2010
Tipo de documento:
Artigo